 |
Panorama of Celltrion headquarters. (Photo=Celltrion) |
[Alpha Biz=(Chicago) Reporter Kim Jisun] IMM Investment Group bought Celltrion shares again. Following the purchase of 200 billion won worth of Celltrion shares this month, the company purchased a large amount of stocks again.
According to Money Today's report on the 29th, IMM Asset Management has secured an additional 85 billion won stake in Celltrion from Singapore's sovereign wealth fund Temasek through a purchasing corporation. Attention is drawn to the background of securing the second large-scale stake after buying 200 billion won worth of Celltrion shares on the 14th.
IMM Investment Group seems to have purchased the stake, judging that Celltrion's stock price has sufficient room to rise. It is also known to consider securing additional shares in the future.
IMM Investment Group actively purchased Celltrion shares to meet the demand for investment rebalancing (adjustment) of Themasek.
Celltrion has recently strengthened its global biosimilar capabilities by launching a new drug for autoimmune diseases, "ZYMFENTRA," in the United States. Seo Jung-jin, chairman of Celltrion Group, is focusing on marketing activities throughout the United States.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
